Atea Pharmaceuticals (AVIR) Insider Trading & Ownership $3.60 +0.15 (+4.35%) As of 04:00 PM Eastern Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Atea Pharmaceuticals (NASDAQ:AVIR) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage18.10%Number OfInsiders Buying(Last 12 Months)0Number OfInsiders Selling(Last 12 Months)2Amount OfInsider Selling(Last 12 Months)$1.17M Get AVIR Insider Trade Alerts Want to know when executives and insiders are buying or selling Atea Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address AVIR Insider Buying and Selling by Quarter Atea Pharmaceuticals Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails12/10/2024Franklin M BergerDirectorSell359,606$2.85$1,024,877.10 9/19/2024Jean-Pierre SommadossiCEOSell1,841$4.00$7,364.00 9/17/2024Jean-Pierre SommadossiCEOSell33,941$4.05$137,461.05 (Data available from 1/1/2013 forward) AVIR Insider Trading Activity - Frequently Asked Questions Who is on Atea Pharmaceuticals' Insider Roster? The list of insiders at Atea Pharmaceuticals includes Andrea Corcoran, Bruce Polsky, Franklin M Berger, Jean-Pierre Sommadossi, and Wayne Foster. Learn more on insiders at AVIR. What percentage of Atea Pharmaceuticals stock is owned by insiders? 18.10% of Atea Pharmaceuticals stock is owned by insiders. Learn more on AVIR's insider holdings. Which Atea Pharmaceuticals insiders have been selling company stock? The following insiders have sold AVIR shares in the last 24 months: Andrea Corcoran ($60,837.12), Bruce Polsky ($61,228.56), Franklin M Berger ($1,024,877.10), Jean-Pierre Sommadossi ($367,952.55), and Wayne Foster ($47,911.68). How much insider selling is happening at Atea Pharmaceuticals? Insiders have sold a total of 499,168 Atea Pharmaceuticals shares in the last 24 months for a total of $1,562,807.01 sold. More Insider Trading Tools from MarketBeat Related Companies Aurinia Pharmaceuticals Insider Trades Enliven Therapeutics Insider Trades AbCellera Biologics Insider Trades WAVE Life Sciences Insider Trades Verve Therapeutics Insider Trades Phibro Animal Health Insider Trades Akebia Therapeutics Insider Trades Collegium Pharmaceutical Insider Trades Intellia Therapeutics Insider Trades CorMedix Insider Trades Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles The Top Insider Sells From Q2: Buy, Sell, or Hold?3 Hot Trades for Insiders, But Are They Good Buys for Investors?Insiders Chase Income and Stability in American Tower—Here’s Why3 Tech Stocks With High and Rising Institutional Interest3 Summer Stocks With Insider Buying and Analyst Support This page (NASDAQ:AVIR) was last updated on 6/30/2025 by MarketBeat.com Staff From Our PartnersAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredNvidia’s Huang: AI is going to need 100x more power12Nvidia CEO Jensen Huang didn't mince words. After Nvidia's latest earnings call, Huang said AI now requires...Weiss Ratings | SponsoredGold Shock (insane new prediction)World Gold Council reports: "No sign" of this catalyst slowing A whopping 73% of Americans report they're "...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atea Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Atea Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AVIR Stock Alerts